Orgenesis (STU:45O) ROCE % : -1,179.04% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Orgenesis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orgenesis's annualized ROCE % for the quarter that ended in Dec. 2023 was -1,179.04%.

Orgenesis ROCE % Historical Data

The historical data trend for Orgenesis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis ROCE % Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-41.69

-164.33

-33.51

-17.37

-165.26

Orgenesis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-1.60	-117.13	-19.69	-129.06	-1,179.04

Orgenesis ROCE % Calculation

Orgenesis's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-57.109	/	( ( (85.836 - 15.019)	+	(13.344 - 15.045) )	/ 2 )
	=	-57.109	/	( (70.817	+	-1.701)	/ 2 )
	=	-57.109	/	34.558
	=	-165.26 %

Orgenesis's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-161.192	/	( ( (42.445 - 13.401)	+	(13.344 - 15.045) )	/ 2 )
	=	-161.192	/	( ( 29.044	+	-1.701 )	/ 2 )
	=	-161.192	/	13.6715
	=	-1,179.04 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Orgenesis (STU:45O) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orgenesis ROCE % Related Terms

Thank you for viewing the detailed overview of Orgenesis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (STU:45O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (STU:45O) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ORGS:USA 45O:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (STU:45O) Headlines

No Headlines